WAT

Accelerates research and development by enabling AI-augmented workflows and automated lab-in-the-loop cycles, already a new and fast-growing source of demand for Waters' instruments and consumables Leverages Waters' unique ability to take an AI-directed experiment from the research bench into development and into Empower™ Software, carrying its audit trail as the molecule moves into downstream, regulated settings Joins Anthropic's Model Hardware Standard (MHS) research program designed to enable AI agents to operate Waters instrument hardware directly and autonomously, cutting instrument integration from weeks to hours Brings Anthropic's Model Context Protocol (MCP) to waters_connect™ Software, enabling scientists to direct Waters instruments through proprietary agents linked to large language models (LLMs), as well as Claude Science MILFORD, Mass., Oct. 13, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that it has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its informatics platform and has joined Anthropic's Model Hardware Standard (MHS) research program.

Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.

MILFORD, Mass., Oct. 1, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q3 2026 financial results conference call on Tuesday, November 3, 2026, at 8:00 a.m.

Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript

WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.

AUSTIN, Texas--(BUSINESS WIRE)--Everlywell, a leader in digital health, today announced a partnership with Waters Corporation to ensure patients have access to the most comprehensive at-home HPV cervical cancer screening tool available in the U.S. today, the Onclarity™ HPV Self-Collection Kit, tested with the BD Onclarity™ HPV Assay.1 The new diagnostic-led solution supports health plans as they expand access to cervical cancer screening and make it easier for eligible members to complete recom.

Enables routine 50+ parameter experiments with BD SpectralFX™ Technology, accelerating breakthrough discoveries in the fight against cancer and other diseases. Minimizes instrument and user differences with first-of-its-kind FACSTruQ™ Technology, achieving industry-leading standardization for greater confidence in results.

MILFORD, Mass., Sept. 11, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D.

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

MILFORD, Mass., Aug. 26, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D.